Article information
Full text is only aviable in PDF
REFERENCES
[1]
Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT).
Recomendaciones ALAT sobre neumonía adquirida en la comunidad.
Arch Bronconeumol, 37 (2001), pp. 340-348
[2]
Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT).
Recomendaciones ALAT sobre exacerbación infecciosa de la EPOC.
Arch Bronconeumol, 37 (2001), pp. 349-357
[3]
BR Celli, GL Snider, J Heffner, B Tiep, I Ziment, B Make, et al.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 152 (1995), pp. S77-S120
[4]
American Thoracic Society.
Guidelines for the management of adults with community-acquired pneumonia.
Am J Respir Crit Care Med, 163 (2001), pp. 1730-1754
[5]
M Miravitlles.
Epidemiology of chronic obstructive pulmonary disease exacerbations.
Clin Pulm Med, 9 (2002), pp. 191-197
[6]
NM Siafakas, P Vermeire, NB Pride, P Paoletti, J Gibson, P Howard, et al.
ERS consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS).
Eur Respir J, 8 (1995), pp. 1398-1420
[7]
British Thoracic Society.
BTS guidelines for the management of chronic obstructive pulmonary disease.
Thorax, 52 (1997), pp. 4-28
[8]
JA Barberà, G Peces-Barba, AGN Agustí, JL Izquierdo, E Monsó, T Montemayor, et al.
Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 37 (2001), pp. 297-316
[9]
MS Balter, RH Hyland, DE Low, PM Renzi, AC Braude, PJ Cole, et al.
Recommendations on the management of chronic bronchitis. A practical guide for Canadian physicians.
Can Med Ass J, 151 (1994), pp. 7-23
[10]
RA Pauwels, AS Buist, PMA Calverley, CR Jenkins, SS Hurd.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[11]
NR Anthonisen, J Manfreda, CPW Warren, ES Hershfield, GKM Harding, NA Nelson.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med, 106 (1987), pp. 196-204
[12]
DM Mannino, C Brown, GA Giovino.
Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data.
Am J Respir Crit Care Med, 156 (1997), pp. 814-818
[13]
V Sobradillo, M Miravitlles, R Gabriel, CA Jiménez-Ruiz, C Villasante, JF Masa, et al.
Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study.
Chest, 118 (2000), pp. 981-989
[14]
AMB Menezes, CG Victoria, M Rigatto.
Prevalence and risk factors for chronic bronchitis in Pelotas, RS, Brazil: a population-based study.
Thorax, 49 (1994), pp. 1217-1221
[15]
R Sansores, JR Pérez-Padilla.
Enfermedad pulmonar obstructiva crónica. Un problema mundial, un enfoque en México, Piensa Ed., (1997),
[16]
INEGI, SSA/DGEI.
Estadísticas vitales. Mortalidad, Estados Unidos Mexicanos, 1997, INEGI, SSA/DGEI, (1998),
[17]
D Maldonado, F Bolívar, A Caballero, A Casas, J Roa, C Salgado.
Sociedad Colombiana de Neumología y Cirugía de Tórax. Recomendaciones para el diagnóstico y manejo del paciente con enfermedad pulmonar obstructiva crónica (EPOC).
Rev Colombe Neumol, 9 (1997), pp. 1-39
[18]
Report number 12681-CH. Chile. The adult health policy change. Human resources operation division. Country department. Latin America and the Caribbean Region. Document of the World Bank. 10 November, 1994.
[19]
J Christopher, L Murray, A López.
Global health statistics.
Harvard University Press,
[20]
Secretaría de Salud.
Dirección General de Epidemiología. Instituto Mexicano de Psiquiatría. Encuesta Nacional de las Adicciones, tabaco, SSA, (1993),
[21]
Department of Health and Human Services. Centers for Diseases Control. Smoking and health in the Americas. USA. Atlanta: DHHS publication number CDC 92-8420, 1992.
[22]
Farías Alburquerque C, Vega Huaman R, Gamboa Aboado R, Pinillos Ashton L, Diouff MA. Plan nacional para prevención y control del tabaquismo en el Perú 2001-2005. Comisión Multisectorial Permanente de Lucha Antitabáquica-COLAT Perú. Ministerio de Salud. Organización Panamericana de Salud. Lima, 2001.
[23]
L Arango, J Luna, G Martínez, M Flores.
Tabaquismo en Guatemala.
Boletín OPS, 2 (1990), pp. 6-9
[24]
EA Carlini, JC Galduróz, AR Noto, SA Nappo.
I levantamento domiciliar sobre o uso de drogas psicotrópicas no Brasil, CLR Balieiro Editores Ltda, (2002),
[25]
B Ostro, JM Sánchez, C Aranda, G Eskaland.
Air pollution and mortality: results from a study in Santiago, Chile.
J Exp Environ Epidemiol, 6 (1996), pp. 97-114
[26]
DP Tashkin, R Detals, M Simmonds, H Liu, AH Coulson, J Sayre, et al.
The UCLA population studies of chronic obstructive respiratory diseases. Impact of air pollution and smoking on annual change in forced expiratory volume in one second.
Am J Respir Crit Care Med, 149 (1994), pp. 1209-1217
[27]
R Pérez-Padilla, J Regalado, S Vadel, P Pare, R Chapela, R Samons, et al.
Exposure to biomass smoke and chronic airway diseases in Mexican women.
Am J Respir Crit Care Med, 154 (1996), pp. 701-706
[28]
RJ Dennis, D Maldonado, S Norman, E Baena, G Martínez.
Wood smoke exposure and risk for chronic obstructive airways disease among women.
Chest, 109 (1996), pp. 115-119
[29]
J Luna, L Arango.
Bronquitis crónica secundaria a la exposición al humo de leña. Archivos Unidad Pulmonar. Hospital Roosevelt.
Revista de Medicina Interna de Guatemala, 3 (1996), pp. 16-20
[30]
DJ Hendrick.
Occupation and chronic obstructive pulmonary disease (COPD).
Thorax, 51 (1996), pp. 947-955
[31]
SO Shaheen, DJP Barker, AW Shiell, FJ Crocker, GA Wield, ST Holgate.
The relationship between pneumonia in early childhood and impaired lung function in late adult life.
Am J Respir Crit Care Med, 149 (1994), pp. 616-619
[32]
P Hodgins, PK Henneberger, M-L Wang, EL Petsonk.
Bronchial responsiveness and five-year FEV1 decline: a study in miners and nonminers.
Am J Respir Crit Care Med, 157 (1998), pp. 1390-1396
[33]
AJ Sandford, TD Weir, PD Paré.
Genetic risk factors for chronic obstructive pulmonary disease.
Eur Respir J, 10 (1997), pp. 1380-1391
[34]
M Miravitlles, R Vidal, Gracia J de.
Enfisema por déficit de alfa-1-antitripsina. Situación actual y nuevas perspectivas para el tratamiento.
Arch Bronconeumol, 28 (1992), pp. 296-302
[35]
M Miravitlles, C Mayordomo, M Artés, L Sánchez-Agudo, F Nicolau, JL Segú, on behalf of the EOLO Group.
Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice.
Respir Med, 93 (1999), pp. 173-179
[36]
E Monsó, J Ruiz, A Rosell, J Monterola, J Fiz, J Morera, et al.
Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.
Am J Respir Crit Care Med, 152 (1995), pp. 1316-1320
[37]
S Sethi, N Evans, BJB Grant, T Murphy.
New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.
N Engl J Med, 347 (2002), pp. 465-471
[38]
J Eller, A Ede, T Schaberg, MS Niederman, H Mauch, H Lode.
Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function.
Chest, 113 (1998), pp. 1542-1548
[39]
M Miravitlles, C Espinosa, E Fernández-Laso, JA Martos, JA Maldonado, M Gallego, Study Group of Bacterial Infection in COPD.
Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD.
Chest, 116 (1999), pp. 40-46
[40]
D Lieberman, D Lieberman, O Shmarkov, Y Gelfer, M Ben-Yaakov, Z Lazarovich, et al.
Serological evidence of Legionella species infection in acute exacerbation of COPD.
Eur Respir J, 19 (2002), pp. 392-397
[41]
N Mogulkoc, S Karakurt, B Isalska, U Bayindir, T Celikel, V Korten, et al.
Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection.
Am J Respir Crit Care Med, 160 (1999), pp. 349-353
[42]
SS Richter, AB Brueggemann, HK Huynh, PR Rhomberg, EM Wingert, R Flamm, et al.
A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions.
Intern J Antimicrob Agents, 13 (1999), pp. 99-107
[43]
M Guzmán-Blanco, JM Casellas, HS Sader.
Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening.
Infect Dis Clin North Am, 14 (2000), pp. 67-81
[44]
T Soler, L Salamanca, G Arbo, E Molina.
Susceptibilidad in vitro de cepas de Streptococcus pneumoniae aisladas de infecciones de las vías aéreas inferiores en el Instituto Nacional del Tórax (INT).
Rev Med Chil, 130 (2002), pp. 304-308
[45]
D Felmingham, RN Gruneberg.
The Alexander Project 19961997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.
J Antimicrob Chemother, 45 (2000), pp. 191-203
[46]
R Wise, D Honeybourne.
Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract.
Eur Respir J, 14 (1999), pp. 221-229
[47]
D Felmingham.
Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT Global Surveillance Study.
J Infect, 44 (2002), pp. 3-10
[48]
H López, H Sader, C Amábile, W Pedreira, JL Muñoz Bellido, JA García Rodríguez, y Grupo MSP-LA.
Actividad in vitro de moxifloxacino frente a patógenos respiratorios en Iberoamérica.
Rev Esp Quimioterap, 15 (2002), pp. 325-334
[49]
RA Stockley, C O'Brien, A Pye, SL Hill.
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.
Chest, 117 (2000), pp. 1638-1645
[50]
PR Murray, JA Washington.
Microscopic and bacteriologic analysis of expectorated sputum.
Mayo Clin Proc, 50 (1975), pp. 339-344
[51]
SG Adams, J Melo, M Luther, A Anzueto.
Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.
Chest, 117 (2000), pp. 1345-1352
[52]
JT MacFarlane, A Colville, A Guion, RM MacFarlane, DH Rose.
Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community.
Lancet, 341 (1993), pp. 511-514
[53]
P Ball, JM Harris, D Lowson, G Tillotson, R Wilson.
Acute infective exacerbations of chronic bronchitis.
Q J Med, 88 (1995), pp. 61-68
[54]
GJ Huchon, G Gialdroni-Grassi, P Léophonte, F Manresa, T Schaberg, M Woodhead.
Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey.
Eur Respir J, 9 (1996), pp. 1590-1595
[55]
NA Dewan, S Rafique, B Kanwar, H Satpathy, K Ryschon, GS Tillotson, et al.
Acute exacerbation of COPD. Factors associated with poor treatment outcome.
Chest, 117 (2000), pp. 662-671
[56]
M Miravitlles, C Murio, T Guerrero, on behalf of the DAFNE Study Group.
Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community.
Eur Respir J, 17 (2001), pp. 928-933
[57]
M Miravitlles.
El fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factores de riesgo e importancia clínica.
Med Clin (Barc), 119 (2002), pp. 304-314
[58]
M Miravitlles, C Murio, T Guerrero, R Gisbert, on behalf of the DAFNE study group.
Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD.
Chest, 121 (2002), pp. 1449-1455
[59]
M Miravitlles, C Murio, T Guerrero, R Gisbert, on behalf of the DAFNE study group.
Costs of chronic bronchitis and COPD. A one year follow-up study.
Chest, 123 (2003), pp. 784-791
[60]
GH Murata, MS Gorby, CO Kapsner, TW Chick, AK Halperin.
A multivariate model for predicting hospital admissions for patients with decompensated chronic obstructive pulmonary disease.
Arch Intern Med, 152 (1992), pp. 82-86
[61]
R Antonelli Incalzi, L Fuso, M de Rosa, F Forastiere, E Rapiti, B Nardecchia, et al.
Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease.
Eur Respir J, 10 (1997), pp. 2794-2800
[62]
E Prescott, P Lange, J Vestbo.
Chronic mucus hypersecretion in COPD and death from pulmonary infection.
Eur Respir J, 8 (1995), pp. 1333-1338
[63]
C Landbo, E Prescott, P Lange, J Vestbo, TP Almidal.
Prognostic value of nutritional status in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 160 (1999), pp. 1856-1861
[64]
R Kessler, M Faller, G Fourgaut, B Mennecier, E Weitzenblum.
Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 159 (1999), pp. 158-164
[65]
M Miravitlles, T Guerrero, C Mayordomo, L Sánchez-Agudo, F Nicolau, JL Segú, on behalf of the EOLO Study Group.
Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis.
Respiration, 67 (2000), pp. 495-501
[66]
AF Connors Jr, NV Dawson, C Thomas, FE Harrel Jr, N Desbiens, WJ Fulkerson, et al.
Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 154 (1996), pp. 959-967
[67]
R Wilson, R Kubin, I Ballin, KM Deppermann, HP Bassaris, P Leophonte, et al.
Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.
J Antimicrob Chemother, 44 (1999), pp. 501-513
[68]
S Chodosh, A Schreurs, G Siami, HW Barkman, A Anzueto, M Shan, et al.
The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Clin Infect Dis, 27 (1998), pp. 730-738
[69]
N Soler, S Ewig, A Torres, X Filella, J González, A Xaubet.
Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease.
Eur Respir J, 14 (1999), pp. 1015-1022
[70]
SW Crooks, DL Bayley, SL Hill, RA Stockley.
Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4.
Eur Respir J, 15 (2000), pp. 274-280
[71]
A Bhowmik, TAR Seemungal, RJ Sapsford, JA Wedzicha.
Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.
Thorax, 55 (2000), pp. 114-120
[72]
P Bresser, TA Out, L van Alphen, HM Jansen, R Lutter.
Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection.
Am J Respir Crit Care Med, 162 (2000), pp. 947-952
[73]
A Anzueto, JA Rizzo, RF Grosman.
The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis.
Clin Infect Dis, 28 (1999), pp. 1344-1345
[74]
IS Patel, TAR Seemungal, M Wilks, SJ Lloyd-Owen, GC Donaldson, JA Wedzicha.
Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.
Thorax, 57 (2002), pp. 759-764
[75]
GC Donaldson, TAR Seemungal, A Bhowmik, JA Wedzicha.
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
Thorax, 57 (2002), pp. 847-852
[76]
TMA Wilkinson, IS Patel, M Wilks, GC Donaldson, JA Wedzicha.
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 167 (2003), pp. 1090-1095
[77]
RA Stockley.
Role of bacteria in the pathogenesis and progression of acute and chronic lung infection.
Thorax, 53 (1998), pp. 58-62
[78]
M Miravitlles.
Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?.
Eur Respir J, 20 (2002), pp. 9-19
[79]
DE Niewoehner, ML Erbland, RH Deupree, D Collins, NJ Gros, RW Light, et al.
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.
N Engl J Med, 340 (1999), pp. 1941-1947
[80]
L Davies, RM Angus, PMA Calverley.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
Lancet, 354 (1999), pp. 456-460
[81]
AT Evans, S Husain, L Durairaj, LS Sadowski, M Charles-Damte, Y Wang.
Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial.
Lancet, 359 (2002), pp. 1648-1654
[82]
L Allegra, C Grassi, E Grossi, E Pozzi, F Blasi, D Frigerio, et al.
Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico.
Ital J Chest Dis, 45 (1991), pp. 138-148
[83]
S Saint, S Bent, E Vittinghoff, D Grady.
Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis.
JAMA, 273 (1995), pp. 957-960
[84]
WA Craig.
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
Clin Infect Dis, 26 (1998), pp. 1-12
[85]
M Miravitlles, C Murio, T Guerrero, JL Segú.
Tratamiento de la bronquitis crónica y la EPOC en atención primaria.
Arch Bronconeumol, 35 (1999), pp. 173-178
[86]
S Kesten, KR Chapman.
Physician perceptions and management of COPD.
Chest, 104 (1993), pp. 254-258
[87]
M Miravitlles.
Moxifloxacin: an antibiotic designed for use in the community.
Eur Respir Rev, 10 (2000), pp. 161-169
[88]
I Odenholt, E Lowdin, O Cards.
Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens.
Antimicrob Agents Chemother, 45 (2001), pp. 23-29
[89]
M Aubier, PM Aldons, A Leak, DD McKeith, B Leroy, M Rangaraju, et al.
Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis.
Respir Med, 96 (2002), pp. 862-871
[90]
N Soler, A Torres, S Ewig, J González, R Celis, M El-Ebiary, et al.
Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.
Am J Respir Crit Care Med, 157 (1998), pp. 1498-1505
[91]
KL Nichol, L Baken, A Nelson.
Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.
Ann Intern Med, 130 (1999), pp. 397-403
These recommendations were made possible by the unrestricted support of Bayer and Aventis.
Members of the ALAT Work Group Coordinators: J.M. Luna (Guatemala) and J.R. Jardim (Brazil). Work Group Members: H. López, C.M. Luna, J.A. Mazzei, and D. Stamboulian (Argentina); J.C. Abreu de Oliveira and J. Pereira (Brazil); A. Díaz, C. Lisboa, and F. Saldías (Chile); D. Maldonado and C. Torres (Colombia); S. Martínez Selmo (Dominican Republic); M. Miravitlles, F. Rodríguez de Castro, and A. Torres (Spain); A. Anzueto and J. Ramírez (USA); M. Díaz, R. Pérez Padilla, A. Ramírez, and R. Sansores (Mexico); I. Carrasco (Panama); A. Matsuno (Peru).
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Recommended
articles
articles
Arch Bronconeumol. 2020;56:651-64
Arch Bronconeumol. 2023;59:232-48
Arch Bronconeumol. 2022;58:11-21
Publish in
Archivos de Bronconeumología
Free access articles
10.1016/j.arbres.2024.09.011
10.1016/j.arbres.2024.09.015
Arch Bronconeumol. 2024;60:539-40
Graphical abstract
Archivos de Bronconeumología is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.
www.publicationethics.org.
Archivos de Bronconeumología follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals